Last reviewed · How we verify

NCT05516654: Klebsiella

Type VI Secretion System in Klebsiella Pneumoniae

Status unknown Last updated 12 April 2023
What this trial tests

trial testing Routine bacteriological cultures in Detection of Type VI Secretion System in K.Pneumoniae in 70 participants. Status unknown.

Timeline
10 September 2022
Primary endpoint
30 January 2023
30 September 2023

Quick facts

Lead sponsorSohag University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment70
Start date10 September 2022
Primary completion30 January 2023
Estimated completion30 September 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Adults 12 Weeks to 90, any sex, with Detection of Type VI Secretion System in K.Pneumoniae or Detection of Relation to Ab Resistance, Biofilm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Klebsiella pneumoniae (K. pneumoniae) is an important opportunistic pathogen contributing to nosocomial and antimicrobial-resistant infections. The increasing prevalence of infections caused by multidrug-resistant K. pneumoniae has emerged as a major clinical and public health threat, while the serous organ and life-threatening infections caused by highly virulent K. pneumoniae have also emerged( Russo and Marr, 2019; Wyres et al., 2020).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05516654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing